Context: Papillary thyroid cancer (PTC) is characterized by a lymphocytic infiltration. PTC patients with lymphocytic infiltration may have a better clinical outcome.
Around 30% of PTC patients additionally suffer from Hashimoto thyroiditis (HT), also known as chronic lymphocytic thyroiditis, the most common autoimmune disease of the thyroid. This frequent coincidence implies further evidence of an important etiological link between PTC and immunological processes in the thyroid. In fact, the reported data about an improved prognosis of PTC patients with present HT imply the question of whether a simultaneously ongoing (auto)immune reaction plays rather a protective role than a destructive one (6, 7) . Owing to these 3 characteristics, that is, the excellent prognosis of this thyroid malignancy, the local lymphocytic infiltration, and the eventual benign association with HT, the hypothesis of an existing antitumor immunity affecting the PTC has been postulated and remains a subject of discussion (8) (9) (10) . Determining the underlying immunological mechanisms will reveal whether the naturally preexisting antitumor immunity helps to approach new therapeutic strategies for patients with advanced PTC. In context with other malignancies, immuno-oncology agents that affect immune cellintrinsic checkpoints and therefore significantly enhance antitumor immunity are already approved therapeutic strategies, for example, CTLA4 and PD-1 blockers (11) (12) (13) . To involve these therapeutic strategies also in the treatment of advanced PTC, it is inevitable to first determine whether the lymphocytic infiltration appears due to antitumor immunity or otherwise due to continuous inflammation caused by autoimmune processes leading eventually to malignancy. In case of HT, we already reported about the evidence of a thyroglobulin (Tg) and thyroperoxidase (TPO) epitope-specific cellular immunity of CD8 + lymphocytes in HT (14) . According to these findings, the first aim of the present study was to characterize the immunologic profile, more precisely the CD8 + T cells in PTC patients by determining the existence of Tg and TPO tumor epitope-specific CD8 + T cells and their response toward stimulation with Tg and TPO peptides. Subsequently, the second aim was to evaluate the clinical impact of our findings by correlating the results with the clinical course of our patients. Finally, numerous susceptibility genes for PTC have been described, with especially HLA polymorphisms showing several correlations, depending on the ethnic background of the examined group of patients (15) . These varying genetic backgrounds of PTCs raise the question of whether tumor epitopespecific immunity might be dependent on particular predisposing HLA types and might not occur in all HLA subtypes involved in the context of PTC. Our third aim therefore is to identify whether epitopespecific immunity is actually dependent on the preexisting HLA type.
Patients and Methods

Patients and controls
Altogether, n = 150 PTC patients (mean age, 52 years; range, 20 to 92 years; 104 females) were included in the study. Of those, n = 22 had active disease estimated by detecting serum Tg $ 0.2 ng/mL (n = 6 patients with Tg $ 0.2 to 1 ng/mL, n = 4 patients with Tg $ 1 to 2 ng/mL, and n = 12 patients with Tg $ 2 ng/mL). Ten PTC patients had distant metastases detected by computed tomography scan. In all other PTC patients included, no current signs of disease were detected at the time of blood sampling. Control groups comprised HT patients (n = 40; mean age, 45 years; range, 24 to 76 years; 31 females) and normal controls (n = 21; mean age, 43 years; range, 22 to 85 years; 13 females). For HLA typing, all PTC patients were correlated to a database containing n = 27,239 whites. Sex was not considered a factor in the statistical analysis of the data. The study has been approved by the Local Ethical Committee of Heinrich Heine University Duesseldorf (approval no. 4244). All experiments have been conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from each patient. HT was defined with the presence of positive TPO autoantibodies (.105 mIU/mL) and/or Tg autoantibodies (.120 mIU/mL) and optional hypoechogenicity in the thyroid sonography.
Tetramer analyses
Peripheral blood mononuclear cells (PBMCs) were isolated by centrifuging heparinized whole blood samples in BD Vacutainer cell preparation tubes (BD Biosciences, San Jose, CA). For fluorescence-activated cell sorter (FACS) analysis, cells were resuspended in 1200 mL of magnetic-activated cell sorting buffer (Miltenyi Biotec) supplemented with 800 mL of fetal calf serum and 200 mL of Fc receptor blocking reagent (Miltenyi Biotec, Bergisch-Gladbach, Germany). Then, 60 mL of cell suspension and 5 mL of tetramer (Glycotope Biotechnology, Heidelberg, Germany) were added to each FACS tube and incubated on ice for 1 hour.
All tetramers and corresponding peptides were selected according to their calculated binding scores calculated with SYFPEITHI (http://www.syfpeithi.de), a database of .7000 peptide sequences known to bind major histocompatibility complex class I and class II molecules. Binding scores of $15 were considered as highly immunogenic [reviewed in Rammensee et al. (16) ]. All tetramers chosen had high binding scores between 29 and 31. The following phycoerythrin-conjugated tetramers and corresponding epitopes were chosen: TPO1 [amino acids (AA) 857 to 865), LLlGGFAGL; TPO2 (AA 3 to 11), ALAVLSVTL; TPO3 (AA 118 to 126), ALSEDLLSl; Tg1 (AA 2355 to 2363), GLLDQVAAL; Tg2 (AA 2750 to 2758), GLREDLLSL; and Tg3 (AA 841 to 850), SLQDVPLAAL. HLA-A0201-specific tetramers were used because of the high frequency within the white population (17) as well as because most commercially available tetramers are restricted to the HLA-A0201 phenotype. Anti-CD8 fluorescein isothiocyanate was added to each of the samples besides anti-immunoglobulin G1 phycoerythrin and anti-CD45 fluorescein isothiocyanate antibodies, which were used as a negative and positive control, respectively. Apart from the tetramers, all other FACS antibodies were purchased from BD Biosciences and incubated as described earlier. Epitope-specific cytotoxic T cells are constantly displayed as a fraction of CD45 + cells in percentages.
Stimulation experiments
To investigate whether the PTC patient's T cells get activated by TPO and Tg, peptide stimulation experiments were performed. Therefore, cancer patient-derived PBMCs were cultured overnight at a density of 1 3 10 6 cells/mL in complete medium [RPMI 1640 GlutaMAX (Gibco, Saranac, NY), 10% fetal calf serum (Gibco), 1% penicillin/streptomycin (Gibco)] containing recombinant human interleukin (IL)-2 (50 U/mL), IL-7 (20 U/mL), and IL-15 (10 ng/mL) and TPO and Tg epitopes, respectively (each 10 mg/mL). For control, PBMCs were also incubated in complete medium together with the control peptide ovalbumin (Biorbyt, Cambridge, UK). All cytokines were purchased from R&D Systems (Minneapolis, USA), and peptides were from Glycotope Biotechnology. The next day, FACS staining was performed using fluorescence-labeled antibodies as described for tetramer analysis.
Measurement of serum thyroid antibodies and thyroglobulin
Measurement of serum TPO and Tg antibodies (Abs) was performed by the Central Laboratory of the University Hospital Duesseldorf using commercial assays (IMMULITE ® 2000 systems).
HLA typing of PTC patients
Peripheral blood cell samples were collected from healthy subjects and patients suffering from PTC. Genomic DNAs were extracted and purified using QIAamp blood kit (Qiagen, Hilden, Germany). The purity of the genomic DNA for each sample was determined by measuring the absorbance at 260 and 280 nm. Samples with the A260/A280 values being in the range of 1.5 to 1.9 were further used and DNA concentration was adjusted to 20 ng/mL.
HLA-DRB1 and HLA-DQB1 intermediate resolution typing was performed by our collaborator (J.E.) by using LABType SSO (One Lambda, Kanoga Park, CA) with Luminex technology (18) according to the manufacturer's protocol. To compare these data with the allele-typing results of the control group, the alleles of the intermediate typing results that do not belong to the common allele group (19) were excluded. In cases where .2 common alleles were present, a sequencing-based typing was performed (20) .
Immunohistology
Serial sections of thyroid gland (7-mm slices) were stained as previously described (21) . Fluorescence microscopic analyses were performed using tetramers in a dilution of 1:40. Slides were mounted by ProLong Gold antifade reagent (Invitrogen, Carlsbad, CA) containing a counterstaining of the cell nuclei by 4 0 ,6 0 -diamidino-2-phenylindole to make the cell nucleus visible. Fluorescence signals were visualized by a Nikon eclipse TE 300 fluorescence microscope affiliated to a Nikon DXM 1200 digital camera (Nikon, Chiyoda, Japan). Lymphocytic infiltration of PTC tissue was stained by our collaborator (A.-C.R, pathologist) by using an automated staining device (Ventana BenchMark ULTRA; Ventana Medical Systems, Tucson, AZ). To investigate existing CD8 + T cells, formalin-fixed paraffinembedded tissue sections (4 to 5 mm) were incubated with monoclonal mouse anti-human CD8 (1:50; clone C8/144B; Dako, Glostrup, Denmark). Lymphocytic infiltration was analyzed in relationship to the tissue section (area, close to the tumor) as well as CD8 infiltration in relationship to the lymphocytic infiltration. 
Statistical analyses
Results
Prevalence of tumor epitope-specific T cells in PTC patients
Based on our previously published data in HT patients, we first determined the number of tumor epitopespecific T cells in the peripheral blood of PTC patients. Tetramer analyses revealed significantly higher numbers of TPO and Tg epitope-specific T cells in the peripheral blood of PTC patients compared with normal controls (Fig. 1) . The frequency of TPO-and Tg-specific CD8 + cytotoxic T cells was (mean) 0.35% 6 0.26% and 0.33% 6 0.24%. For comparison, normal controls revealed TPO-and Tg-specific CD8 + T cell numbers of 0.16% 6 0.12% and 0.16% 6 0.14%. Importantly, and as previously described, HT patients revealed only slightly more TPO-and Tg-specific T cells [0.45% 6 0.36% and 0.40% 6 0.31%; Fig. 1(A) ] compared with PTC patients. Figure 1(B) shows a detailed analysis of all tetramers tested: PTC and AIT patients exhibited significant elevated numbers of TPO1 (PTC, P , 0.05; AIT, P , 0.05), TPO2 (PTC, P , 0.005; AIT, P , 0.05), TPO3 (PTC, P , 0.05), and Tg3 (PTC, P , 0.0005; AIT, P , 0.05) tetramer-positive CD8 + T cells in comparison with healthy subjects. We also investigated the number of tumor epitopespecific CD8 + T cells in PTC patients according to their tumor activity. PTC patients with active disease (serum Tg detectable . 0.2 ng/mL) had similar numbers of tetramer-positive cells (sum of tetramer-positive CD8 + T cells, mean 6 standard deviation: TPO, 0.35% 6 0.33%; Tg, 0.34 6 0.27%) compared with serum Tgnegative patients (TPO, 0.32% 6 0.22%; Tg, 0.30 6 0.23%; P = not significant; data not shown). Similar data were seen depending on morphological detectable tumor spread. Tetramer analyses in PTC patients with positive computed tomography scan also revealed similar data (TPO, 0.34% 6 0.30%; Tg, 0.32% 6 0.18%) compared with those without (TPO, 0.33% 6 0.25%; Tg, 0.30 6 0.23%; P = not significant; data not shown).
HLA class II-restricted tumor spread
Because antitumor immunity is restricted to the HLA class II phenotype as well, we next performed HLA typing and correlated these data to the clinical course, for example, to the patient's tumor-node-metastasis stages. With regard to the tumor size or lymph node involvement, there were no significant differences for any HLA-DR or HLA-DQ subtype. However, and most important, with regard to metastatic spread, significant differences were found for 3 HLA phenotypes: the risk of developing distant metastases was much lower in HLA-DQB1*03-positive patients (2.5% of PTC patients) compared with HLA-DQB1*03-negative PTC patients [14.8% of PTC patients; Fig. 2(A) ; relative risk, 0.170; 95% confidence interval (CI), 0.037 to 0.755; P , 0.05]. In contrast, the risk of developing distant metastases was higher in HLA-DRB1*03-positive patients (20.0% of PTC patients; relative risk, 4.400, 95% CI, 1.378 to 14.05; P , 0.05) and HLA-DQB1*02-positive patients (15.4% of PTC patients; relative risk, 3.692; 95% CI, 1.102 to 12.38; P , 0.05) compared with negative PTC patients (4.5% and 4.2%, respectively, of PTC patients) [ Fig. 2 
(B) and 2(C)].
Correlation analyses between HLA phenotype and tumor epitope-specific immunity
Irrespective of the HLA type, we next performed in vitro T cell stimulation assays in n = 39 PTC patients. As shown in Figure 3 We also investigated tumor epitope-specific immunity in HLA-DRB1*03-positive and HLA-DQB1*02-positive PTC patients showing a higher risk of developing distant metastases [ Fig. 2(B) and 2(C) ]. In HLA-DRB1*03-positive patients no significant T cell response could be detected compared with HLA-DRB1*03-negative patients. In HLA-DQB1*02-positive PTC patients a slight increase of epitope-specific T cell immunity could be detected (0.80% to 1.164%, P , 0.05; data not shown), which was however lower compared with HLA-DQB1*03-positive PTC patients [ Fig. 3(B) ].
Detection of epitope-specific CD8 + T cells in tumor sites
One characteristic feature of PTC is its lymphocytic infiltration (22, 23) . When performing immunofluorescence analyses of 21 PTC specimens, we found CD8 + T cell infiltrations in 95.3% of patients (20 of 21 patients) ranging from 1% up to 40% (mean 6 standard deviation, 7.7% 6 10.9%) of the individual sections. These infiltrations also displayed a proportion of CD8 + T cells of up to 40% (Supplemental Table 1 ; Supplemental Fig. 1) . By comparing the strength of lymphocytic infiltration with the number of peripheral epitope-specific T cells as well as the HLA type, no correlation was seen. Because antitumor immunity arises in regional lymph nodes by presentation of tumor epitopes by antigen-presenting cells, tetramer staining was done in these tissues. In this study, TPO and Tg epitope-specific CD8 + T lymphocytes could be detected (Fig. 4) .
Discussion
Lymphocytic infiltration in PTC is a well-known phenomenon (10) . The aim of the present study was to characterize tumor epitope-specific CD8 + T cell immunity in PTC patients and to correlate these results with their clinical course. We were able to demonstrate the protective role of HLA-DQB1*03 against tumor spread in PTC patients, as those patients have a decreased risk for distant metastases. The better clinical course in HLA-DQB1*03-positive patients correlated with an increased tumor epitope-specific immunity, which could be proven by tetramer analyses. Interestingly, these tumor-specific CD8 + T cells could also be detected in tumor-infiltrated lymph nodes. We also showed an increased risk of developing distant metastases in HLA-DRB1*03-positive and HLA-DQB1*02-positive PTC patients, which correlates with a diminished tumor-specific immunity in these patients. These data indicate a close connection between antitumor immunity and the clinical course in PTC patients. In our study, we demonstrate PTC patients revealing numbers of Tg and TPO epitope-specific T cells within the peripheral blood similar to those for HT patients. This finding, together with the knowledge of a combined appearance of lymphocytic infiltrations in tumor sites and the increased risk of PTC in HT, raises the question of an immunological link between both entities. Potential mechanisms involved in this process have recently been described by us (10) and others (23, 24) . The rarely occurring distant metastases in PTC and the good overall prognosis (10-year survival of .90%) support this hypothesis (25) .
The appearance of autoimmunity in cancer patients is well known, especially in melanoma patients who may synchronously develop autoimmune vitiligo, a condition that results in loss of skin pigmentation, owing to the presence of target-specific cytotoxic T cells. This has led to the conclusion that vitiligo may be a visible effect of a spontaneous antitumoral immune response in melanoma patients (26) . In fact, melanoma patients with vitiligo often have a better clinical outcome compared with melanoma patients without vitiligo (27) . Importantly, this phenomenon has also been described in melanoma patients treated by immunotherapy with interferon (28), as cytokine-treated melanoma patients with autoimmunity have a largely improved overall survival compared with those without.
This mechanism, also called "tumor defense-induced autoimmunity," might also occur in the thyroid gland in the course of antitumor immunity [reviewed in Ehlers and Schott (10) ]. In this study, genetic predisposition to thyroid autoimmune disease could enhance autoimmunity during therapeutic induction of tumor immunity, as shown in thyroiditis-susceptible mice (29) . This hypothesis is in line with our results, as the HLA-DQB1*03 phenotype has already been described to be associated with HT (30, 31) . Recently, a meta-analysis by Lee et al. (32) investigated the correlation between PTC and histologically proven HT. HT was found in 23% of PTC patients and was significantly associated with a longer duration of recurrence-free survival. This observation is supported by another study in which immune cell infiltration was related to a better prognosis for patients with PTC (33), a proof for the ongoing antitumor immune response.
In our study, most of our PTC patients were free of disease, as Tg levels were not detectable without any morphological sign of tumor persistence. Only 15% (22 of 150) of patients had detectable Tg levels and/or morphologically detectable distant metastasis (n = 10). Tumor-specific CD8 + T cell immunity was detectable in all subgroups of PTC patients without showing any significant differences including subgroup analyses of PTC patients with and without serum Tg increase (data not shown). This indicates a persistence of antitumor immunity irrespective of any tumor activation. This phenomenon is well-known from other tumors, for example, from melanoma where cytotoxic T cells are detectable in cancer patients with long-term remission (34) (35) (36) . Another important issue is the presence of Tg Abs in PTC. Tg Abs may appear in PTC patients in the course of disease [reviewed in Ehlers and Schott (10) ]. These Abs interfere with Tg and, therefore, represent a clinical problem for the follow-up of PTC patients. Tg Abs have, however, also been postulated as a sign of humoral antitumor immunity in PTC patients. In the past it has been shown that elevated Tg Abs appear to serve as a useful marker for recurrent or persistent differentiated thyroid cancer in patients with undetectable serum Tg levels (37). Most recently, Hsieh and Wang (38) reported on active disease in PTC patients with persistently high and increasing Tg Abs. An association between PTC and Tg Abs, however, could not be reproduced by others (39, 40) . Another study performed a more detailed analysis, investigating Tg Ab epitope restriction in detail (41) . The authors found a less favorable prognosis in PTC patients with a Tg Ab restriction compared with those with a more unspecific antitumor immunity. In our study, we could not identify a correlation between epitope-specific cellular immunity and Tg Abs (data not shown).
There are limitations of our study. Of 150 PTC patients, only 22 patients had active disease defined as patients with detectable serum Tg and/or morphological detectable metastatic spread. Because rarely occurring metastatic spread is one of the hallmarks of PTC, it was difficult to identify more patients. A larger number of PTC patients with morphological detectable disease would have possibly revealed a more detailed view. This might also be true for the limited number of paraffin sections used for immunological staining. A larger number would have possibly revealed a significance between T-cell infiltration and epitope-specific immunity. Another limitation is the retrospective design of the study with analyses of patients who have been treated for PTC in the past. This approach will of course not influence HLA typing of our patients. It may have an impact on the antitumor immunity in these patients. By including more patients with active disease (with increased Tg serum levels and metastatic spread), we would, however, expect even higher numbers of epitope-specific T cells.
Taken together, our study clearly shows an association between the HLA-DQB1*03 phenotype, epitope-specific antitumor immunity, and the clinical course of PTC patients. Based on these data, new immune therapies with blockers of immune cell-intrinsic checkpoints (such as CTLA4 and PD-1 ligand) might be applied to PTC patients with radioiodine-refractory disease. Tumor epitope-specific CD8 + T cells could be monitored by tetramer analyses as shown in our study. Similar approaches have already successfully been applied to patients with malignant melanoma.
